A Single-center, Open-label, Steady-state Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
At a glance
- Drugs SH-229 (Primary) ; Daclatasvir
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Nanjing Sanhome Pharmaceutical
- 28 Nov 2018 Planned primary completion date changed from 19 Jan 2019 to 19 Dec 2018.
- 28 Nov 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 28 Nov 2018 New trial record